ArticleClinical research in cardiology : official journal of the German Cardiac Society2026
Conformity with guideline-directed medical therapy and clinical outcomes in secondary cardiovascular prevention-results of a German claims data analysis.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsClinical guidelines for secondary cardiovascular (CV) prevention provide recommendations for medical treatment to improve patient prognosis. This retrospective German study aimed to identify the level of guideline implementation in patients suffering from myocardial infarction (MI), stroke or transient ischemic attack (TIA), and the impact of guideline-directed medical therapy (GDMT) adherence on CV outcomes or death.
methodsData from an anonymized claims dataset from a German statutory health fund were analyzed regarding GDMT for the above patient population. Patients were followed for at least one year after their first MI and/or stroke/TIA. For clinical outcomes analysis, a 1:1 propensity score matching (PSM) was applied between patients receiving a GDMT and those with a treatment not in line with GDMT (nGDMT).
resultsData from 56,671 patients with previous MI and 96,257 patients with previous stroke/TIA were included; 50.1% of MI patients and 28.5% of stroke/TIA patients received a GDMT. Fewer major CV events (MACE), defined as death or recurrent stroke, TIA, or MI, occurred in patients who received a GDMT that was started at least 30 days after the first event, compared to those who did not receive such a treatment (both groups p < 0.001).
conclusionsGDMT concerning secondary CV prevention is poorly implemented in daily medical practice, resulting in a higher CV event rate for those who do not receive such a recommended treatment. From a clinical, patient and health-economic perspective, all relevant parties should improve guideline implementation in clinical practice.
Indexed as
Identifiers
42257861What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.